Abstract 2087P
Background
Cancer symptoms (CS) impose a significant burden on patients, affecting their quality of life and financial stability. The purpose of this study was to investigate the impact of common CS on the physical and financial well-being of patients who frequently rely on medications to manage their cancer-related symptoms.
Methods
A cross-sectional, descriptive study was conducted between January and October 2022. The study aimed to identify patient-administered drugs for managing cancer treatment toxicities and associated symptoms. It assessed six common symptoms: anorexia/cachexia, fatigue, nausea/vomiting, pain, constipation, and diarrhea. Demographic data were collected, along with cancer type and active treatment status. Symptom assessment used PERSONS questionnaire, while financial distress (FD) was analyzed with the COST questionnaire.
Results
A total of 211 patients completed the questionnaires, providing valuable insights into their symptom management. However, 183 patients, relied on prescription drugs to alleviate their symptoms. Cancer pain (CP) management was the primary concern for 45% of the patients, followed by constipation, which affected 28% of them. Significantly, the analysis revealed a strong association between CP and lower PERSONS scores, suggesting a negative impact on overall well-being. CP was also correlated with FD, unlike other symptom categories, which did not show statistically significant correlations. Healthcare costs were primarily attributed to pain management, including visits to healthcare professionals and prescription medications. Pain-related expenses contributed to financial strain, resulting in increased out-of-pocket costs and potential income loss due to reduced work productivity or inability to work.
Conclusions
This survey highlights the profound impact of CP on the quality of life and financial well-being of cancer patients. Collaborative efforts among healthcare professionals and policymakers are crucial in developing integrated approaches that ensure accessible and affordable pain management for cancer patients, thus alleviating their suffering and reducing the financial burden associated with pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Giusti.
Funding
Has not received any funding.
Disclosure
R. Giusti: Financial Interests, Personal, Expert Testimony, Advisory Board for Clinician's expertise on Drug Management: Roche; Financial Interests, Personal, Invited Speaker, Publication fee for open access manuscript: Molteni; Financial Interests, Personal, Advisory Board, Advisory Board: Novartis, Pfizer; Financial Interests, Personal, Invited Speaker to national and international congress: Angelini Pharma; Financial Interests, Personal, Expert Testimony, Expert testimony on Drug Management: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06